Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (3) | Back to Search
Clinical pharmacokinetics and dosages of amikacin in cystic fibrosis pediatric patients.
- In: Hospital Pharmacy Section - Posters
- At: Beijing (China) (2007)
- Type: Poster
- Poster code: HPS-P-049
- By: CACERES GUIDO, Paulo Arturo (Hospital de Pediatria Garrahan, Buenos Aires, Argentina)
- Co-author(s): Perez, Mariel (Hospital de Pediatria Garrahan, BUENOS AIRES, Argentina)
Halac, Alicia (Hospital de Pediatria Garrahan, BUENOS AIRES, Argentina)
Castaños, Claudio (Hospital de Pediatria Garrahan, BUENOS AIRES, Argentina)
Gimenez, Cristina (Hospital de Pediatria Garrahan, BUENOS AIRES, Argentina)
Moroni, Alicia (Hospital de Pediatria Garrahan, BUENOS AIRES, Argentina)
Díaz, A (Hospital de Pediatria Garrahan, BUENOS AIRES, Argentina)
Licciardone, Nieves (Hospital de Pediatria Garrahan, BUENOS AIRES, Argentina)
Fernándes, Andrea (Hospital de Pediatria Garrahan, BUENOS AIRES, Argentina)
Currás, Verónica (Facultad de Farmacia y Bioquímica (UBA), BUENOS AIRES, Argentina)
Bramuglia, Guillermo (Facultad de Farmacia y Bioquímica (UBA), BUENOS AIRES, Argentina) - Abstract:
Aims: amikacin (AMK) is an aminoglycoside antibiotic widely used in the management of Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients. Our goal was to estimate AMK pharmacokinetic (PK) parameters and to calculate suitable dose schemes for CF pediatric patients at Garrahan Pediatric´s Hospital during 21 months (July 2005..
The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023